Akari Therapeutics PLC (AKTX) – What Are Researchers Saying About This Stock?

Akari Therapeutics PLC (NASDAQ:AKTX) has received an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $32.33.

Several research analysts have recently issued reports on the company. Alliance Global Partners upgraded Akari Therapeutics to a “strong-buy” rating in a research report on Friday, September 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Akari Therapeutics in a report on Friday, October 2nd. Wall Street Zen raised Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Finally, Maxim Group raised Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Monday, July 20th.

Akari Therapeutics Stock Up 1.6%

Shares of AKTX opened at $8.23 on Friday. The company’s 50 day moving average price is $9.30 and its 200 day moving average price is $9.31. Akari Therapeutics has a 52 week low of $3.02 and a 52 week high of $33.60.

About Akari Therapeutics

Akari Therapeutics, Plc (NASDAQ: AKTX) is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on regulating the complement system and inflammatory pathways that contribute to tissue damage.

Akari’s lead investigational product is nomacopan, a recombinant small protein designed to inhibit complement component 5 (C5) and leukotriene B4 (LTB4). The company is also developing a long-acting formulation known as PAS-nomacopan.